<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185236</url>
  </required_header>
  <id_info>
    <org_study_id>H-1007-100-324</org_study_id>
    <nct_id>NCT01185236</nct_id>
  </id_info>
  <brief_title>Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes</brief_title>
  <official_title>A Single Center, Open Label, Randomized Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, open label, randomized, clinical trial comparing ApoB/ApoA ratio of Vytorin
      10/20mg vs atorvastatin 20mg treatment.

      DM2 patients will be screened for inclusion criteria. Patients (n=66 in each arm) will be
      randomized to either Ezetimibe/simvastatin 10/20mg or atorvastatin 20mg after 4 week washout
      or TLC period. Primary and secondary endpoints will be assessed at week 12.

      Primary endpoint:

      1) change of ApoB/ApoA ratio at week 12.

      Secondary endpoint:

        1. Change of lipid parameters (TC, LDL-C, HDL-C, TG, apoB 48) at week 12.

        2. Change of HbA1C at week 12.

        3. Change of HOMA index at week 12

           - HOMA =[Fasting insulin (mIU/L) × Fasting glucose (mmol/L)] / 22.5

        4. Change of hsCRP at week 12

        5. Safety assessment

      Hypotheses:

        -  Three months treatment of Vytorin 10/20mg will be superior to atorvastatin 20mg in
           ApoB/ApoA ratio.

        -  In DM patients, Ezetimibe/Simvastatin Combination will be well-tolerated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of ApoB/ApoA1</measure>
    <time_frame>after 12 weeks' treatment</time_frame>
    <description>change of ApoB/ApoA1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of lipid profile</measure>
    <time_frame>12weeks</time_frame>
    <description>change of total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglyceride, and APO B48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of HbA1c</measure>
    <time_frame>12weeks</time_frame>
    <description>change of HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of HOMA index</measure>
    <time_frame>12weeks</time_frame>
    <description>HOMA =[Fasting insulin (mIU/L) × Fasting glucose (mmol/L)] / 22.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of hsCRP</measure>
    <time_frame>12weeks</time_frame>
    <description>change of hsCRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>during 12weeks of treatment</time_frame>
    <description>CK elevation, Liver funtion test abnormality, and muscle realted adverse reactions and symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Type 2 Diabetes Mellitus Without Insulin Treatment</condition>
  <arm_group>
    <arm_group_label>simvastatin/ezetimibe (vytorin) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vytorin 10/20mg po once daily for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin 20mg po once daily for 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin/ezetimibe</intervention_name>
    <description>simvastatin/ezetimibe 10/20mg once daily for 12weeks</description>
    <arm_group_label>simvastatin/ezetimibe (vytorin) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 20mg</intervention_name>
    <description>atorvastatin 20mg once daily for 12weeks</description>
    <arm_group_label>atorvastatin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 DM

          2. Hypercholesterolemia (baseline screening LDL-C &gt; 100 mg/dL)

          3. In case of medication, stable doses of oral hypoglycemic agents for at least three
             months

          4. HbA1c &lt;8.5%

          5. Age: 20-80

        Exclusion Criteria:

          1. Chronic renal failure: creatinine &gt; 3.0 mg/dL

          2. Serious liver disease (&gt; x3 LFT UNL)

          3. Congestive heart failure

          4. Stroke or MI/coronary intervention during the preceding 3 months.

          5. CK &gt; x 2.5 UNL

          6. Unstable hypo/hyperthyroidism

          7. Pregnant/lactating woman, or woman intending to become pregnant

          8. Subject with any clinically significant condition or situation, in the opinion of the
             investigator, would interfere with the study evaluations or optimal participation in
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyun-Jae Kang</last_name>
    <phone>82-2-2072-2279</phone>
    <email>nowkang@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul national university hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hyun-Jae Kang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>August 18, 2010</last_update_submitted>
  <last_update_submitted_qc>August 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hyun-Jae Kang, Associate professor</name_title>
    <organization>Seoul ntional university hospital</organization>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 25, 2011</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 22, 2011</submitted>
    <returned>December 23, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

